Sandoz stock enters Brazil with first semaglutide launch

Published on 11/10/2026 at 11:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sandoz stock gains a new growth option as Owozy enters Brazil for type-2 diabetes. The company expects no material contribution this year.

Brazil launch expands GLP-1 strategy

Sandoz launched Owozy, its first semaglutide treatment, in Brazil for adults with type-2 diabetes.
Local partner Biolab & Co will commercialize the product, which was developed by Adalvo.
Sandoz expects no material financial contribution from the launch this year.

Sandoz, CH1243598427, Illustration mit AI erstellt.

Sandoz launched its first semaglutide treatment in Brazil on Monday, November 9, 2026, opening a new commercial route in the fast-growing GLP-1 market. The company announced the launch of Owozy in a release carried by Finanzen.net.

Owozy targets Brazil diabetes care

Owozy is a semaglutide solution for injection for adults with insufficiently controlled type-2 diabetes. The product was developed by Adalvo and received approval from Brazil's Agência Nacional de Vigilância Sanitária on July 29, 2026.

Sandoz will commercialize Owozy through Biolab & Co under a distribution and promotion agreement signed earlier this year. The treatment is supplied in a pre-filled multi-dose disposable pen and is administered once weekly according to the approved product information and medical advice.

Sandoz said Brazil has more than 16.5 million adults living with diabetes. The company estimates the country's GLP-1 market at USD 2.7 billion, citing IQVIA data. That market opportunity gives the launch strategic relevance, although the immediate earnings effect is expected to remain limited.

Limited near-term earnings impact

Richard Saynor, Sandoz's chief executive, described the launch as a milestone for the company and patients in Brazil. He linked Owozy to Sandoz's ambition to become a leading player in generic GLP-1 medicines and to the broader strategy presented at the company's September 2026 Capital Markets Day.

The company nevertheless expects no material financial contribution from the semaglutide launch in 2026. For investors, the announcement therefore adds a portfolio and market-access option rather than a near-term earnings catalyst. Prescription uptake, distribution performance and further GLP-1 launches will determine whether the strategic opportunity develops into a meaningful revenue stream.

Current trading remains a separate signal

Sandoz stock traded at 91.35 euros on Lang & Schwarz at 11:15 CET on Tuesday, November 10, 2026. The quote provides a current market reference, while the launch announcement itself points to longer-term portfolio expansion rather than an immediate financial contribution.